NUTRITIONAL COMPOSITION AND INFANT FORMULA FOR STIMULATING BRAIN MYELINATION Russian patent published in 2022 - IPC A23L33/115 A23L33/15 A23L33/16 

FIELD: food industry.

SUBSTANCE: invention relates to nutritional compositions for use in order to prevent, reduce the risk or mitigate a suboptimal trajectory of de novo myelination in a subject fed with a mixture. The use of a synthetic nutritional composition containing a fatty acid compound, which is monoacylglycerin, and/or diacylglycerin, and/or triacylglycerin, including docosahexaenoic acid (hereinafter – DHA) from 60 to 350 mg/100 g of dry weight of the composition, is proposed to prevent, reduce the risk or mitigate a suboptimal trajectory of de novo myelination in a subject fed with a mixture. The trajectory of de novo myelination is suboptimal, when the distance between any equivalent and/or identical measurement points of an infant trajectory and a trajectory achieved in infants who are exclusively breastfed during their first (3) months of life exceeds 50%. The synthetic nutritional composition contains DHA from 60 to 350 mg/100 g, iron – at least 5 mg/100 g, folic acid – at least 100 mcg/kg, vitamin B12 – at least 5 mcg/100 g, and sphingomyelin – at least 300 mg/kg. The composition is a composition selected from a group consisting of: infant formula, milk for complementary feeding, a composition for infants that is intended for addition or dilution with human breast milk, and a food product intended for consumption by an infant and/or a child either separately or in combination with human breast milk. An infant is an infant under the age of 12 months, and a child is a person aged from 1 to 18 years and preferably from 1 to 5 years.

EFFECT: invention makes it possible to optimize the amount/degree of myelination in the subject.

11 cl, 13 tbl, 7 ex, 63 dwg